SCHEMBL4635305

SCHEMBL4635305

O=C(O)c1cccc(O)c1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC28A3 Q9HAS3 3/20 0.61
HIF1A Q16665 1/20 0.54
SLC5A1 P13866 2/20 0.52
TYR P14679 1/20 0.51
SLC5A2 P31639 1/20 0.51
USP2 O75604 4/20 0.50
HKDC1 Q2TB90 3/20 0.50
L3MBTL1 Q9Y468 3/20 0.50
TNNI3 P19429 2/20 0.50
TNNT2 P45379 2/20 0.50
TNNC1 P63316 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
KDM4E B2RXH2 1/20 0.50
MEN1 O00255 1/20 0.50
LMNA P02545 1/20 0.50
GLA P06280 1/20 0.50
CYP3A4 P08684 1/20 0.50
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4636191 0.87 SLC28A3 (0.61) SLC28A3HIF1ASLC5A1SLC5A2NPC1
SCHEMBL15662640 0.86 SLC28A3 (0.51) SLC28A3HIF1ASLC5A1TYRSLC5A2
SCHEMBL15661272 0.86 SLC5A2 (0.51) SLC28A3SLC5A1TYRSLC5A2EPHX2
SCHEMBL29078207 0.85 SLC28A3 (0.64) SLC28A3HIF1ASLC5A1TYRMEN1
SCHEMBL4636160 0.85 SLC28A3 (0.58) SLC28A3HIF1ASLC5A1TYRSLC5A2
SCHEMBL18322971 0.84 SLC28A3 (0.52) SLC28A3HIF1ASLC5A1TYRSLC5A2
SCHEMBL4635629 0.84 SLC28A3 (0.57) SLC28A3HIF1ASLC5A1TYRSLC5A2
SCHEMBL941002 0.84 SLC28A3 (0.62) SLC28A3HIF1ASLC5A1TYRSLC5A2
SCHEMBL4635870 0.83 SLC28A3 (0.56) SLC28A3HIF1ASLC5A1TYRSLC5A2
SCHEMBL27695466 0.82 SLC28A3 (0.47) SLC28A3SLC5A1TYRSLC5A2USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1932514-B1 PHARMACEUTICAL PREPARATION FOR EXTERNAL APPLICATION TO SKIN COMPRISING PHOSPHORYLATED SUGAR EZAKI GLICO CO (JP) 2018-11-14 EP disclosed
US-20140023602-A1 EXTERNAL PREPARATION FOR SKIN CONTAINING A PHOSPHORYLATED SACCHARIDE EZAKI GLICO CO., LTD. (JP) 2014-01-23 US disclosed
US-20080274068-A1 External Preparation for Skin Containing a Phosphorlated Saccharide EZAKI GLICO CO., LTD. (JP) 2008-11-06 US disclosed
EP-1932514-A1 PHARMACEUTICAL PREPARATION FOR EXTERNAL APPLICATION TO SKIN COMPRISING PHOSPHORYLATED SUGAR Ezaki Glico Co., Ltd. (JP) 2008-06-18 EP disclosed
EP-0649648-B1 Skin whitening agents containing glycosides SHISEIDO CO LTD (JP) 2001-09-19 EP disclosed
US-5700784-A GLYCOSIDES OF HYDROXYSALICYLIC ACID AND/OR GLYCOSIDES OF ESTERS OF HYDROXYSALICYLIC ACID; EXCELLENT WHITENING EFFECT AND SKIN CARE EFFECT SHISEIDO CO., LTD. (JP) 1997-12-23 US disclosed
EP-0649648-A2 Skin whitening agents containing glycosides SHISEIDO COMPANY LIMITED (JP) 1995-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140023602-A1 EXTERNAL PREPARATION FOR SKIN CONTAINING A PHOSPHORYLATED SACCHARIDE SI, CUTA, CD44 SLC28A3 1164/4885HIF1A 634/4885SLC5A1 723/4885
US-20080274068-A1 External Preparation for Skin Containing a Phosphorlated Saccharide CUTA, SI, CD44 SLC28A3 977/4885HIF1A 658/4885SLC5A1 589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.